Insider transactions

EDGAR

HARVARD BIOSCIENCE, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
5 transactions, 41,000 shares
Sum of shares × price per share: 202,353.5
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–13 of 13

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-06-09 Filed 2026-06-12Eade Katherine A. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)16,5560.00
0

Derived: shares × price per share. Exact value 0.00.

58,669Direct (D) No
F1, F2, F3
  • F1 Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
  • F2 Includes (a) the award described in footnote (1) above and (b) 42,113 shares of common stock beneficially owned by the Reporting Person.
  • F3 On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 42,113 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and 311,126 shares of common stock beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Open filing 0001171843-26-004082 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Snider William Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)16,5560.00
0

Derived: shares × price per share. Exact value 0.00.

48,556Direct (D) No
F1, F2, F3
  • F1 Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
  • F2 Includes (a) the award described in footnote (1) above, (b) 12,525 shares of common stock purchased on March 16, 2026, (c) 8,475 shares of common stock purchased on March 17, 2026, and (d) 11,000 restricted stock units that fully vest on December 17, 2026.
  • F3 On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(d) were previously reported as covering 110,000 restricted stock units. This number has been adjusted to reflect the stock split that occurred on March 13, 2026.
Open filing 0001171843-26-004060 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Benson Seth Benjamin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)16,5560.00
0

Derived: shares × price per share. Exact value 0.00.

27,556Direct (D) No
F1, F2, F3
  • F1 Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
  • F2 Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person.
  • F3 On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Open filing 0001171843-26-004056 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Gagnon Robert E. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)16,5560.00
0

Derived: shares × price per share. Exact value 0.00.

27,556Direct (D) No
F1, F2, F3
  • F1 Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
  • F2 Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person.
  • F3 On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Open filing 0001171843-26-004057 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11DENELSKY STEPHEN J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)16,5560.00
0

Derived: shares × price per share. Exact value 0.00.

37,556Direct (D) No
F1, F2, F3
  • F1 Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
  • F2 Includes (a) the award described in footnote (1) above, (b) 10,000 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on September 5, 2026.
  • F3 On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Open filing 0001171843-26-004058 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-04-01Frost Mark T Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)30,0000.00
0

Derived: shares × price per share. Exact value 0.00.

47,500Direct (D) No
F1, F2
  • F1 Includes (a) an award granting 30,000 restricted stock units (RSUs) that will vest in three equal installments on March 20, 2027, 2028, and 2029, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 5,000 shares of common stock purchased on March 16, 2026, (c) 10,000 RSUs that will vest on May 12, 2026, and (d) 2,500 shares of common stock beneficially owned by the Reporting Person.
  • F2 On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 10,000 RSUs referenced in Footnote 1(c) were previously reported as covering 100,000 RSUs and the 2,500 shares of common stock referenced in Footnote 1(d) were previously reported as covering 25,000 shares of common stock. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Open filing 0001171843-26-002156 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-03-23Duke John D Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)75,0000—180,000Direct (D) No
F1
  • F1 See remarks
Open filing 0001171843-26-001843 Read from the filing’s XML Dispute this row
2026-03-17 Filed 2026-03-18Snider William Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)8,4754.85
41,103.75

Derived: shares × price per share. Exact value 41103.75.

32,000Direct (D) No
F2, F4, F5
  • F2 The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.80 to $4.95, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.
  • F4 Includes (a) 12,525 shares of common stock purchased on March 16, 2026, (b) 8,475 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on December 17, 2026.
  • F5 On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Open filing 0001171843-26-001689 Read from the filing’s XML Dispute this row
2026-03-17 Filed 2026-03-18DENELSKY STEPHEN J Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)10,0004.87
48,700

Derived: shares × price per share. Exact value 48700.00.

21,000Direct (D) No
F1, F2
  • F1 Includes (a) 10,000 shares of common stock purchased on March 17, 2026 and (b) 11,000 restricted stock units that fully vest on September 5, 2026.
  • F2 On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Open filing 0001171843-26-001732 Read from the filing’s XML Dispute this row
2026-03-16 Filed 2026-04-01Frost Mark T Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)5,0005.00
25,000

Derived: shares × price per share. Exact value 25000.00.

17,500Direct (D) No
F1, F2
  • F1 Includes (a) 5,000 shares of common stock purchased on March 16, 2026, (b) 10,000 restricted stock units that will vest on May 12, 2026, and (c) 2,500 shares of common stock beneficially owned by the Reporting Person.
  • F2 On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 10,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 100,000 restricted stock units and the 2,500 shares of common stock referenced in Footnote 1(c) were previously reported as covering 25,000 shares of common stock. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Open filing 0001171843-26-002155 Read from the filing’s XML Dispute this row
2026-03-16 Filed 2026-03-18Snider William Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)12,5254.99
62,499.75

Derived: shares × price per share. Exact value 62499.75.

23,525Direct (D) No
F1, F3, F5
  • F1 The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.85 to $5.00, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the Securities and Exchange Commission (SEC) staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.
  • F3 Includes (a) 12,525 shares of common stock purchased on March 16, 2026, and (b) 11,000 restricted stock units that fully vest on December 17, 2026.
  • F5 On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Open filing 0001171843-26-001689 Read from the filing’s XML Dispute this row
2026-03-16 Filed 2026-03-17Duke John D Director · Officer: Chief Executive Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)5,0005.01
25,050

Derived: shares × price per share. Exact value 25050.00.

105,000Direct (D) No
F1, F2
  • F1 Includes (a) 5,000 shares of common stock purchased on March 16, 2026, (b) an award of 50,000 restricted stock units (RSUs) that will vest in three equal installments on August 8, 2026, 2027 and 2028, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person and (c) an award of 50,000 RSUs with performance based vesting conditions. These RSUs will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from August 8, 2025 to the earlier of (i) July 30, 2028, and (ii) the date of a change of control, measured relative to the Russell2000 index, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these RSUs that may be earned is reported above; the maximum amount is 150% of the number reported.
  • F2 On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 50,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 500,000 restricted stock units and the 50,000 restricted stock units referenced in Footnote 1(c) were previously reported as covering 500,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Open filing 0001171843-26-001645 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-30Snider William Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)110,0000.00
0

Derived: shares × price per share. Exact value 0.00.

110,000Direct (D) No
F1
  • F1 Represents an award of 110,000 restricted stock units that fully vest on December 17, 2026.
Open filing 0001171843-25-008127 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–33 of 33

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
WEBER CAPITAL MANAGEMENT LLC /ADV 299,816 SH2,374,543 dollarsLower by 11,045 Prior quarter: 310,861Open filing 0001941040-26-000751 Filed 2026-10-19 Dispute this row
NANO CAP NEW MILLENNIUM GROWTH FUND L P Partly reported under another manager200,000 SH1,584,000 dollarsHigher by 56,918 Prior quarter: 143,082Open filing 0001277890-26-000005 Filed 2026-11-13 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager179,614 SH1,421 dollarsUnchanged Prior quarter: 179,614Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 172,065 SH1,362,755 dollarsHigher by 2,440 Prior quarter: 169,625Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Meros Investment Management, LP 169,280 SH1,340,698 dollarsLower by 13,712 Prior quarter: 182,992Open filing 0001911372-26-000006 Filed 2026-11-17 Dispute this row
Mink Brook Asset Management LLC 124,199 SH983,656 dollarsHigher by 90,830 Prior quarter: 33,369Open filing 0001437749-26-036940 Filed 2026-11-13 Dispute this row
CORSAIR CAPITAL MANAGEMENT, L.P. 122,810 SH972,655 dollarsUnchanged Prior quarter: 122,810Open filing 0001013594-26-001187 Filed 2026-11-16 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager94,327 SH747,070 dollarsLower by 5,000 Prior quarter: 99,327Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
TWO SIGMA INVESTMENTS, LP 85,535 SH677,437 dollarsLower by 29,010 Prior quarter: 114,545Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager61,893 SH490,193 dollarsHigher by 59 Prior quarter: 61,834Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager46,753 SH370,376 dollarsLower by 802 Prior quarter: 47,555Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
VANGUARD FIDUCIARY TRUST CO 27,730 SH219,622 dollarsUnchanged Prior quarter: 27,730Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
MILLENNIUM MANAGEMENT LLC 27,060 SH214,315 dollarsLower by 5,560 Prior quarter: 32,620Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
ESSEX INVESTMENT MANAGEMENT CO LLC Partly reported under another manager26,973 SH213,626 dollarsUnchanged Prior quarter: 26,973Open filing 0000201772-26-000007 Filed 2026-10-19 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager24,811 SH196,503 dollarsHigher by 11,560 Prior quarter: 13,251Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Williams Novak Wealth Management, LLC 16,555 SH131,116 dollarsLower by 4,394 Prior quarter: 20,949Open filing 0001085146-26-000868 Filed 2026-10-09 Dispute this row
RBF Capital, LLC 16,000 SH126,720 dollarsUnchanged Prior quarter: 16,000Open filing 0001062993-26-005971 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager14,932 SH118,261 dollarsUnchanged Prior quarter: 14,932Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
UBS Group AG Partly reported under another manager12,404 SH98,240 dollarsLower by 5,177 Prior quarter: 17,581Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
GSA CAPITAL PARTNERS LLP 11,499 SH91 dollarsNot in the prior quarter’s filings read Open filing 0001362033-26-000013 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP 10,753 SH85,164 dollarsNot in the prior quarter’s filings read Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager10,230 SH81,021 dollarsUnchanged Prior quarter: 10,230Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
MORGAN STANLEY Partly reported under another manager9,909 SH78,479 dollarsHigher by 8,282 Prior quarter: 1,627Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
FMR LLC Partly reported under another manager3,086 SH24,441 dollarsLower by 93 Prior quarter: 3,179Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Vanguard Global Advisers, LLC 1,221 SH9,670 dollarsUnchanged Prior quarter: 1,221Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
SBI Securities Co., Ltd. 866 SH6,859 dollarsUnchanged Prior quarter: 866Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
Brown Shipley Co Ltd Partly reported under another manager478 SH3,786 dollarsUnchanged Prior quarter: 478Open filing 0001912970-26-000004 Filed 2026-10-09 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager451 SH3,572 dollarsLower by 129 Prior quarter: 580Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
NISA INVESTMENT ADVISORS, LLC 228 SH1,806 dollarsUnchanged Prior quarter: 228Open filing 0000937615-26-000007 Filed 2026-10-20 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager129 SH1,000 dollarsHigher by 114 Prior quarter: 15Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager66 SH523 dollarsUnchanged Prior quarter: 66Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager32 SH255 dollarsLower by 163 Prior quarter: 195Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
SHP Wealth Management 10 SH62 dollarsUnchanged Prior quarter: 10Open filing 0001807060-26-000007 Filed 2026-11-19 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • JANE STREET GROUP, LLC 13,982 SH
  • GOLDMAN SACHS GROUP INC 10,657 SH
  • GROUP ONE TRADING LLC 2,300 SH
  • GROUP ONE TRADING LLC 240 SH
  • PENSION WEALTH MANAGEMENT ADVISORS, INC. 225 SH
  • BARCLAYS PLC 26 SH
  • PNC Financial Services Group, Inc. 14 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Leviticus Partners LP Common Stock5.2235,000.0009/14/2026 Filed 2026-09-22SCHEDULE 13G/AAmendment 8Open filing 0001019432-26-000013 Dispute this row
Leviticus Partners LP Common Stock7.63,401,601.0012/31/2025 Filed 2026-02-12SCHEDULE 13G/AAmendment 6Open filing 0001019432-26-000003 Dispute this row
BroadOak Income Fund, L.P. Common Stock, par value $0.01 per share15.34810,000.0012/17/2025 Filed 2026-03-23SCHEDULE 13DOpen filing 0001171843-26-001839 Dispute this row
BroadOak Fund VI, L.P. Common Stock, par value $0.01 per share0.3315,000.0012/17/2025 Filed 2026-03-23SCHEDULE 13DOpen filing 0001171843-26-001839 Dispute this row
BroadOak Capital Partners, LLC Common Stock, par value $0.01 per share15.57825,000.0012/17/2025 Filed 2026-03-23SCHEDULE 13DOpen filing 0001171843-26-001839 Dispute this row
William Snider Common Stock, par value $0.01 per share15.97846,000.0012/17/2025 Filed 2026-03-23SCHEDULE 13DOpen filing 0001171843-26-001839 Dispute this row
Leviticus Partners LP Common Stock7.53,350,000.0010/30/2025 Filed 2025-11-03SCHEDULE 13G/AAmendment 5Open filing 0001019432-25-000028 Dispute this row
Leviticus Partners LP Common Stock9.24,047,535.0008/06/2025 Filed 2025-08-07SCHEDULE 13G/AAmendment 4Open filing 0001019432-25-000022 Dispute this row
AMH Equity LLC Common Stock9.24,047,535.0008/06/2025 Filed 2025-08-07SCHEDULE 13G/AAmendment 4Open filing 0001019432-25-000022 Dispute this row
BlackRock, Inc. Common Stock2.51,113,92606/30/2025 Filed 2025-07-17SCHEDULE 13G/AAmendment 1Open filing 0002052113-25-003189 Dispute this row
Leviticus Partners LP Common Stock6.5293,676.0005/12/2025 Filed 2026-05-14SCHEDULE 13G/AAmendment 7Open filing 0001019432-26-000010 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,748,233 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015164,615
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to HARVARD BIOSCIENCE, INC.